Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIRIDEX Corporation

IRIDEX Corporation

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.6574 USD -0.02 ( 3.32%)
Last update at 2026-11-06T21:00:00Z
VOLUME
21726
Market Cap
11.11M

Momentum Score

…

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.66
Low
0.70
High
52 Week Price Range
0.62
Low
1.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

IRIDEX Corporation develops and markets laser-based systems and consumables for treating retinal diseases and glaucoma. Long-term growth may be supported by aging populations, rising prevalence of diabetic eye disease and glaucoma, recurring consumable revenue and gradual international adoption, while ongoing product development could support incremental share gains.
Principal risks include execution and financial constraints typical of smaller medical-device companies, competition from larger ophthalmic suppliers, dependence on a limited product portfolio and sensitivity to regulatory or reimbursement changes.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.68
Dividend Yield
-
Revenue TTM
51.57M
Revenue Per Share
2.99
Gross Profit TTM
18.53M
Debt / Equity
0.92
ROE
-73.15%
Net Debt
-1.50M
ROCE
-27.47%
Diluted EPS TTM
-0.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -4.38M -8.84M -9.48M -7.48M -5.18M
Net income -4.44M -8.91M -9.57M -7.55M -5.22M
Selling general administrative 7.73M 9.78M 8.75M 7.56M 8.86M
Selling and marketing expenses 10.40M 12.58M 16.24M 18.18M 14.64M
Gross profit 19.31M 19.50M 21.81M 25.37M 22.83M
Reconciled depreciation 1.55M 1.42M 2.03M 1.38M 0.80M
Ebit -4.38M -8.84M -9.48M -8.93M -8.34M
Ebitda -2.83M -7.42M -7.45M -7.54M -7.53M
Depreciation and amortization 1.55M 1.42M 2.03M 1.38M 0.80M
Operating income -2.57M -8.30M -10.01M -7.54M -7.53M
Other operating expenses 55.25M 56.97M 61.88M 64.51M 61.44M
Interest expense - - - 1.44M 3.15M
Tax provision 0.06M 0.07M 0.09M 0.07M 0.04M
Income tax expense 0.06M 0.07M 0.09M 0.07M 0.04M
Total revenue 52.67M 48.67M 51.87M 56.97M 53.90M
Total operating expenses 21.88M 27.80M 31.81M 32.91M 30.36M
Cost of revenue 33.37M 29.17M 30.06M 31.60M 31.07M
Total other income expense net -1.81M -0.54M 0.53M 0.06M 2.35M
Net income from continuing ops -4.44M -8.91M -9.57M -7.55M -5.22M
Net income applicable to common shares - - - -7.55M -5.22M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 29.15M 29.14M 34.44M 42.29M 48.69M
Intangible assets 0.98M 1.31M 1.64M 1.98M 2.21M
Other current assets 1.80M 1.96M 0.86M 1.47M 1.07M
Total liab 24.23M 27.04M 24.91M 25.06M 25.39M
Total stockholder equity 4.92M 2.10M 9.52M 17.23M 23.30M
Other current liab 3.45M 3.11M 5.08M 5.13M 5.96M
Common stock 0.17M 0.17M 0.17M 0.17M 0.17M
Capital stock 6.17M 0.17M 0.17M 0.17M 0.17M
Retained earnings -92.45M -88.01M -79.04M -69.72M -62.17M
Other liab - - - 11.87M 11.01M
Good will 0.96M 0.96M 0.96M 0.96M 0.96M
Other assets - - - 1.46M 0.27M
Cash 6.03M 2.39M 7.03M 13.92M 23.85M
Total current liabilities 13.21M 16.56M 12.97M 12.45M 12.65M
Current deferred revenue 3.68M 3.49M 2.40M 2.41M 2.35M
Net debt -1.50M 2.26M -4.29M -12.15M -21.20M
Short term debt 0.70M 2.83M 0.99M 1.04M 0.93M
Short long term debt - 1.73M - - -
Short long term debt total 4.53M 4.64M 2.75M 1.77M 2.66M
Other stockholder equity 91.21M 89.88M 88.44M 86.80M 85.25M
Property plant equipment - - - 2.13M 2.99M
Total current assets 25.25M 23.56M 27.45M 35.77M 42.25M
Net tangible assets - - - 14.29M 20.13M
Net receivables 9.54M 8.39M 9.65M 9.77M 9.72M
Long term debt 3.73M 1.00M - - -
Inventory 7.88M 10.82M 9.91M 10.61M 7.61M
Accounts payable 5.38M 6.99M 4.50M 3.87M 3.40M
Accumulated other comprehensive income -0.01M 0.05M -0.05M -0.02M 0.04M
Non currrent assets other 1.12M 1.39M 1.40M 1.46M 0.27M
Non current assets total 3.90M 5.57M 6.99M 6.52M 6.43M
Capital lease obligations 0.80M 1.91M 2.75M 1.77M 2.66M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01M -0.11M -0.29M -5.56M
Change to liabilities - - - 1.95M 13.68M
Total cashflows from investing activities -0.14M -0.01M -0.11M -0.29M -5.56M
Net borrowings -3.96M -0.22M 0.00M - -
Total cash from financing activities 5.96M 2.60M -0.01M -0.07M 9.47M
Change to operating activities - - - -4.29M -1.12M
Net income -4.44M -8.91M -9.57M -7.55M -5.22M
Change in cash 3.64M -4.65M -6.89M -9.93M 12.23M
Begin period cash flow 2.39M 7.03M 13.92M 23.85M 11.63M
End period cash flow 6.03M 2.39M 7.03M 13.92M 23.85M
Total cash from operating activities -2.12M -7.29M -6.75M -9.52M 8.22M
Issuance of capital stock 10.00M 3.37M 0.00M 0.00M 9.88M
Depreciation 1.55M 1.42M 2.03M 1.38M 0.80M
Other cashflows from investing activities -0.14M -0.01M - - -
Change to inventory 2.12M -0.91M 0.64M -3.02M 0.27M
Change to account receivables -1.15M 1.26M 0.36M 0.20M 0.64M
Sale purchase of stock - - -0.09M - -
Other cashflows from financing activities -0.07M -0.55M -0.09M -9.95M -0.41M
Change to netincome - - - 1.81M -0.83M
Capital expenditures 0.14M 0.01M 0.11M 0.29M 0.21M
Change in working capital -2.38M -1.37M -0.86M -5.16M 13.47M
Stock based compensation 0.78M 1.24M 1.65M 1.62M 1.63M
Other non cash items 2.38M 0.33M 1.65M 0.19M -2.46M
Free cash flow -2.26M -7.30M -6.85M -9.80M 8.00M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IRIX
IRIDEX Corporation		 -0.02
3.32%		 0.66 - 769.23 0.22 331.20 0.32 -3.61
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

1212 Terra Bella Avenue, Mountain View, CA, United States, 94043

650 940 4700

https://www.iridex.com

93

Name Title Year Born
Mr. David I. Bruce Pres, CEO & Director 1959
Mr. Fuad Ahmad Interim Chief Financial Officer 1970
Mr. Patrick Mercer Chief Operating Officer 1972
Ms. Leigh Salvo Head of Investor Relations NA
Mr. David I. Bruce President, CEO & Director 1959
Mr. Scott A. Shuda J.D. Executive Chairman 1965
Mr. Patrick Mercer CEO, President & Director 1972
Mr. Romeo R. Dizon Chief Financial Officer 1958
Mr. Bassem BouHabib SVP of International Sales & Business Development 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…